Detalhe da pesquisa
1.
Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy.
Hum Mol Genet;
29(4): 605-617, 2020 03 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31814004
2.
Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.
Hum Mol Genet;
27(7): 1276-1289, 2018 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29415125
3.
Identification and characterization of Nanobodies targeting the EphA4 receptor.
J Biol Chem;
292(27): 11452-11465, 2017 07 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28526745
4.
Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
Biochim Biophys Acta;
1862(7): 1255-66, 2016 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27063456
5.
Reciprocal negative cross-talk between liver X receptors (LXRs) and STAT1: effects on IFN-γ-induced inflammatory responses and LXR-dependent gene expression.
J Immunol;
190(12): 6520-32, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23686490
6.
Heterozygous Deletion of EphrinA5 Does Not Improve Functional Recovery After Experimental Stroke.
Stroke;
50(4): e101, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30852969
7.
Brain region- and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington's disease.
Neurobiol Dis;
52: 219-28, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23295856
8.
Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics.
Pharmaceutics;
15(6)2023 Jun 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37376196
9.
Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
J Neurosci;
31(22): 8150-62, 2011 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21632937
10.
VHHs as tools for therapeutic protein delivery to the central nervous system.
Fluids Barriers CNS;
19(1): 79, 2022 Oct 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36192747
11.
AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS.
Mol Ther Methods Clin Dev;
20: 508-519, 2021 Mar 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33614825
12.
Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis.
Sci Rep;
9(1): 14112, 2019 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31575928
13.
Lowering EphA4 Does Not Ameliorate Disease in a Mouse Model for Severe Spinal Muscular Atrophy.
Front Neurosci;
13: 1233, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31803009
14.
Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
Acta Neuropathol Commun;
7(1): 114, 2019 07 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31300041
15.
EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease.
Alzheimers Res Ther;
11(1): 102, 2019 12 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31831046
16.
Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration.
Mol Neurobiol;
55(10): 7728-7742, 2018 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29460266
17.
Prevalence and demographics of methicillin resistant Staphylococcus aureus in culturable skin and soft tissue infections in an urban emergency department.
BMC Emerg Med;
7: 19, 2007 Oct 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17974027
18.
RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.
Mol Neurobiol;
53(5): 2857-2868, 2016 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25876513
19.
Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
J Clin Invest;
126(11): 4319-4330, 2016 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27721240
20.
Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS).
Exp Neurol;
262 Pt B: 138-51, 2014 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25017368